|
|||||
|
|
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients |
|
| Authors: | Julia L Marcus Leo B Hurley Scott Chamberland Jamila H Champsi Laura C Gittleman Daniel G Korn Jennifer B Lai Jennifer O Lam Mary Patricia Pauly Charles P Quesenberry Joanna Ready Varun Saxena Suk I Seo David J Witt Michael J Silverberg |
| Institution: | 1. Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts;3. Kaiser Permanente Division of Research, Oakland, California;4. Kaiser Permanente Northern California, Regional Pharmacy, Oakland, California;6. Kaiser Permanente South San Francisco Medical Center, South San Francisco, California;5. Kaiser Permanente Northern California, Medical Group Support Services, Oakland, California;7. Kaiser Permanente San Rafael Medical Center, San Rafael, California;12. Kaiser Permanente Sacramento Medical Center, Sacramento, California;8. Kaiser Permanente Santa Clara Medical Center, Santa Clara, California;10. Kaiser Permanente Antioch Medical Center, Antioch, California; Kaiser Permanente Walnut Creek Medical Center, Walnut Creek, California |
| Abstract: | |
| Keywords: | Direct-acting Antiviral Agents Sustained Virologic Response Race Effectiveness AASLD American Association for the Study of Liver Diseases CI confidence interval HCV hepatitis C virus HIV human immunodeficiency virus ICD International Classification of Diseases IDSA Infectious Diseases Society for America KPNC Kaiser Permanente Northern California LDV/SOF ledipasvir/sofosbuvir RR risk ratio SVR sustained virologic response |
| 本文献已被 ScienceDirect 等数据库收录！ | |